ReviewDrug delivery and translational research2021
Antimicrobial nanomedicine for ocular bacterial and fungal infection.
Review in Drug delivery and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Nanosuspension-based Ocular Therapeutics for Infection Control: Integrating Mucin Interactions and Tear Film Dynamics.AAPS PharmSciTech · 2026Review
- Comprehensive insights into the role of nanocarriers in advancing azole-based ocular therapeutics.RSC advances · 2025Review
- An injectable shape-adaptive hydrogel system for subconjunctival injuries:Materials today. Bio · 2025Article
- Genetic determinants of silver nanoparticle resistance and the impact of gamma irradiation on nanoparticle stability.BMC microbiology · 2025Article
- Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases.International journal of nanomedicine · 2025Review
- Recent Nanotechnological Trends in the Management of Microbial Keratitis.Journal of ophthalmic & vision research · 2024Review
- Metallic nano-warriors: Innovations in nanoparticle-based ocular antimicrobials.Materials today. Bio · 2024Review
- A water transfer printing method for contact lenses surface 2D MXene modification to resist bacterial infection and inflammation.Science advances · 2024Article
- Application of metagenomic next-generation sequencing in the diagnosis of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Prophylaxis of posterior capsule opacification through autophagy activation with indomethacin-eluting intraocular lens.Bioactive materials · 2023Article
- Caspofungin-Loaded Formulations for Treating Ocular Infections Caused byGels (Basel, Switzerland) · 2023Article
- Recent advances in targeted antibacterial therapy basing on nanomaterials.Exploration (Beijing, China) · 2023Review
- ε-poly-L-lysine-modified polydopamine nanoparticles for targeted photothermal therapy of drug-resistant bacterial keratitis.Bioengineering & translational medicine · 2023Article
- Emergence of microbial resistance against nanoparticles: Mechanisms and strategies.Frontiers in microbiology · 2023Review
- Vision Defense: Efficient Antibacterial AIEgens Induced Early Immune Response for Bacterial Endophthalmitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Anti-Oxidative and Anti-Inflammatory Micelles: Break the Dry Eye Vicious Cycle.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Ferrostatin-1-loaded liposome for treatment of corneal alkali burn via targeting ferroptosis.Bioengineering & translational medicine · 2022Article
- Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification.Bioactive materials · 2022Article
- Efficient antibacterial AIEgens induced ROS for selective photodynamic treatment of bacterial keratitis.Frontiers in chemistry · 2022Article
- Recent Advances of Intraocular Lens Materials and Surface Modification in Cataract Surgery.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular infection induced by bacteria and fungi is a major cause of visual impairment and blindness. Topical administration of antibiotics remains the first-line treatment, as effective eradication of pathogens is the core of the anti-infection strategy. Whereas, eye drops lack efficiency and have relatively low bioavailability. Intraocular injection may cause concurrent ocular damage and secondary infection. In addition, antibiotic-based management can be limited by the low sensitivity to multidrug-resistant bacteria. Nanomedicine is proposed as a prospective, effective, and noninvasive platform to mediate ocular delivery and combat pathogen or even resistant strains. Nanomedicine can not only carry antimicrobial agents to fight against pathogens but also directly active microbicidal capability, killing pathogens. More importantly, by modification, nanomedicine can achieve enhanced residence time and release time on the cornea, and easy penetration through corneal tissues into anterior and posterior segments of the eye, thus improving the therapeutic effect for ocular infection. In this review, several categories of antimicrobial nanomedicine are systematically discussed, where the efficiency and possibility of further embellishment and improvement to adapt to clinical use are also investigated. All in all, novel antimicrobial nanomedicine provides potent and prospective ways to manage severe and refractory ocular infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.